Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial

被引:12
|
作者
Huang, Yu [1 ]
Chen, Jinnan [1 ]
Ding, Zhaohui [1 ]
Chen, Xi [1 ]
Liang, Xiao [1 ]
Zeng, Xin [2 ]
Xu, Fei [2 ]
Han, Yuehua [3 ]
Lu, Hong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab Di, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China
[3] Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Helicobacter pylori; Minocycline; Tetracycline; Rescue therapy; ANTIBIOTIC-RESISTANCE; 2ND-LINE REGIMENS; AMOXICILLIN; METRONIDAZOLE; ERADICATION; DOXYCYCLINE; INFECTION; EFFICACY; SAFETY; SUSCEPTIBILITY;
D O I
10.1007/s00535-023-01991-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundTo compare the efficacy and tolerability of minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) rescue treatment.MethodsThis study was a multi-center, randomized-controlled, non-inferiority trial. Refractory H. pylori-infected subjects with multiple treatment-failure were randomly (1:1) allocated to receive 14-day therapy with esomeprazole 20 mg b.i.d, bismuth 220 mg b.i.d, plus metronidazole 400 mg q.i.d and minocycline 100 mg b.i.d (minocycline group) or tetracycline 500 mg q.i.d (tetracycline group). Primary outcome was H. pylori eradication rate evaluated by C-13-urea breath test at least 6 weeks after the end of treatment. Antibiotic resistance was determined using E test method.ResultsThree hundred and sixty-eight subjects were randomized. The eradication rates in minocycline group and tetracycline group were 88.0% (162/184, 95% CI 83.3-92.8%) and 88.6% (163/184, 95% CI 83.9-93.2%) in intention-to-treat analysis, 98.0% (149/152, 95% CI 95.8-100%) and 97.4% (150/154, 95% CI 94.9-99.9%) in per-protocol analysis, 93.1% (162/174, 95% CI 89.3-96.9%) and 93.1% (163/175, 95% CI 89.4-96.9%) in modified intention-to-treat analysis. Minocycline, tetracycline and metronidazole resistance rates were 0.7%, 1.4% and 89.6%, respectively. Non-inferiority of minocycline was confirmed (P < 0.025). Metronidazole resistance did not affect the efficacy of either therapy. The two therapies exhibited comparable frequencies of adverse events (55.4% vs. 53.3%); almost half of them were mild. Dizziness was the most common adverse events in the minocycline group.ConclusionsMinocycline can be an alternative for tetracycline in bismuth-containing quadruple therapy for H. pylori empirical rescue treatment, irrespective of metronidazole resistance. However, relatively high incidence of adverse events in both regimens should be emphasized.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 50 条
  • [41] Comparison of Bismuth Containing Quadruple Therapy and Tailored Therapy for Helicobacter pylori Eradication According to Clarithromycin Resistance: A Prospective Randomized Controlled Trial
    Bang, Byoung Wook
    Ko, Eun Jung
    Kwon, Kye Sook
    Shin, Yong Woon
    Kim, Hyung Kil
    DIGESTION, 2020, 101 (01) : 97 - 97
  • [42] Comparison of Bismuth containing quadruple therapy and tailored therapy for Helicobacter pylori eradication according to clarithromycin resistance; a prospective randomized controlled trial
    Kim, H.
    Bang, B.
    Ko, E.
    Shin, Y.
    HELICOBACTER, 2018, 23
  • [43] Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication
    Ozturk, Oguzhan
    Doganay, Levent
    Colak, Yasar
    Enc, Feruze Yilmaz
    Ulasoglu, Celal
    Ozdil, Kamil
    Tuncer, Ilyas
    ARAB JOURNAL OF GASTROENTEROLOGY, 2017, 18 (02) : 62 - 67
  • [44] Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial
    Guan, Jia-Lun
    Hu, Yun-Lian
    An, Ping
    He, Qiong
    Long, Hui
    Zhou, Lin
    Chen, Zhi-Fen
    Xiong, Jian-Guang
    Wu, Shi-Sheng
    Ding, Xiang-Wu
    Luo, He-Sheng
    Li, Pei-Yuan
    PHARMACOTHERAPY, 2022, 42 (03): : 224 - 232
  • [45] Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
    Suo Baojun
    Tian Xueli
    Zhang Hua
    Lu Haoping
    Li Cailing
    Zhang Yuxin
    Ren Xinlu
    Yao Xingyu
    Zhou Liya
    Song Zhiqiang
    中华医学杂志英文版, 2023, 136 (08)
  • [46] Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
    Suo, Baojun
    Tian, Xueli
    Zhang, Hua
    Lu, Haoping
    Li, Cailing
    Zhang, Yuxin
    Ren, Xinlu
    Yao, Xingyu
    Zhou, Liya
    Song, Zhiqiang
    CHINESE MEDICAL JOURNAL, 2023, 136 (08) : 933 - 940
  • [47] Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
    Yang, Jing
    Zhang, Yi
    Fan, Ling
    Zhu, Yang-Jie
    Wang, Ting-Yi
    Wang, Xing-Wei
    Chen, Dong-Feng
    Lan, Chun-Hui
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (03): : 437 - 445
  • [48] Bismuth quadruple regimen containing furazolidone and tetracycline as a promising strategy for Helicobacter pylori initial and rescue therapy: A prospective cohort study
    Peng, Jianxiang
    Xie, Jinliang
    Wu, Shuang
    Liu, Dingwei
    Yang, Kaijie
    Huang, Deqiang
    Xie, Yong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 17 - 17
  • [49] Bismuth quadruple regimen containing furazolidone and tetracycline as a promising strategy for Helicobacter pylori initial and rescue therapy: A prospective cohort study
    Peng, Jianxiang
    Xie, Jinliang
    Wu, Shuang
    Liu, Dingwei
    Yang, Kaijie
    Huang, Deqiang
    Xie, Yong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 17 - 17
  • [50] One-week triple vs. quadruple therapy for Helicobacter pylori infection -: a randomized trial
    Calvet, X
    Ducons, J
    Guardiola, J
    Tito, L
    Andreu, V
    Bory, F
    Guirao, R
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (07) : 1261 - 1267